Table 2 Intraoperative characteristics
From: Myocardial protection with phosphocreatine in high-risk cardiac surgery patients: a randomized trial
Placebo (n = 63) | Phosphocreatine (n = 57) | p-value | |
|---|---|---|---|
Cardiopulmonary bypass time, minutes – median (IQR) | 110 (88-133) | 99 (87-118) | 0.28 |
Aortic cross-clamp time, minutes – median (IQR) | 79 (62-99) | 75 (62-90) | 0.41 |
Volume of cardioplegia, ml – median (IQR) | 2100 (2100-2100) | 2100 (2100-2100) | 0.34 |
Mitral valve surgery | |||
repair, n (%) | 20 (33%) | 20 (36%) | 0.74 |
replacement, n (%) | 41 (65%) | 36 (63%) | 0.83 |
Aortic valve surgery | |||
repair, n (%) | 5 (7.9%) | 2 (3.5%) | 0.30 |
replacement, n (%) | 24 (38%) | 19 (33%) | 0.60 |
Tricuspid valve surgery | |||
repair, n (%) | 42 (67%) | 39 (68%) | 0.84 |
replacement, n (%) | 4 (6.3%) | 4 (7.0%) | 0.88 |
Other additional surgeries, n (%) | 16 (25%) | 14 (25%) | 0.90 |
Need for defibrillation after aorta declamping, n (%) | 25 (40%) | 22 (39%) | 0.90 |
Ventricular fibrillation while still in theatre after protamine administration, n | 1 (1.6%) | 1 (1.7%) | 0.94 |
Ventricular tachycardia while still in theatre after protamine administration, n | 1 (1.6%) | 0 | 0.34 |
AV block grade 1, n (%) | 0 | 1 (1.8%) | 0.29 |
AV block grade 2, n (%) | 2 (3.2%) | 1 (1.8%) | 0.62 |
AV block grade 3, n (%) | 9 (14%) | 7 (12%) | 0.75 |
Inotropic score at the end of surgery – median (IQR) | 5 (3-13) | 5 (2-9) | 0.47 |